Abstracts tagged "juvenile idiopathic arthritis (JIA) and safety"

Abstract Number: 2380 • 2018 ACR/ARHP Annual Meeting
The Safety Profile of Adalimumab across Geographic Regions and Dosing Administrations Among Patients with Juvenile Idiopathic Arthritis Enrolled in a Registry
Hermine I. Brunner¹, Nicola Ruperto², Kabita Nanda³, Mary Toth⁴, Ivan Foeldvari⁵, John F. Bohnsack⁶, Diana Milojevic⁷, Daniel J Kingsbury⁸, Katherine A. Marzan⁹, Elizabeth Chalom¹⁰, Gerd Horneff¹¹, Rolf M. Kuester¹², Jason A Dare¹³, Maria Trachana¹⁴, Mareike Bereswill¹⁵, Hartmut Kupper¹⁵, Daniel J Lovell¹⁶ and Alberto Martini², ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Gaslini Institute and Pediatric Rheumatology International Trials Organisation, Genoa, Italy, ³Seattle Children's Hospital, Seattle, WA, ⁴Nemours Children’s Hospital, Orlando, FL, ⁵Hamburg Center for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ⁶University of Utah, Salt Lake City, UT, ⁷Johns Hopkins All Children’s Hospital, St. Petersburg, FL, ⁸Randall Children’s Hospital, Portland, OR, ⁹Children's Hospital Los Angeles, Los Angeles, CA, ¹⁰The Pediatric Specialty Center at Saint Barnabas, West Orange, NJ, ¹¹Asklepios Children's Clinic, Sankt Augustin, Germany, ¹²Orthopädiezentrum Altona, Hamburg, Germany, ¹³Arkansas Children’s Hospital, Little Rock, AR, ¹⁴Hippokration General Hospital, Aristotle University, Thessaloniki, Greece, ¹⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ¹⁶PRCSG, Cincinnati Children’s Hospital Medical Center, Cinncinnati, OH
Background/Purpose: Adalimumab (ADA) has been approved for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) with long-term use often required to maintain disease control. The…
Abstract Number: 287 • 2013 ACR/ARHP Annual Meeting
Long-Term Evaluation Of Cardiac Function In Juvenile Idiopathic Arthritis Under Anti-Tumor Necrosis Factor Therapy
Alessandro C. Lianza¹, Nadia E. Aikawa², Julio C. B. Moraes³, Gabriela N. Leal⁴, Samira S. Morhy⁵, Eloisa Bonfa⁶ and Clovis A. Silva⁷, ¹Radiology, University of São Paulo, Sao Paulo, Brazil, ²Rheumatology, University of São Paulo, Sao Paulo, Brazil, ³Reumatologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Radiology Division, University of São Paulo, Sao Paulo, Brazil, ⁵Radiology Unit, University of São Paulo, Sao Paulo, Brazil, ⁶Rheumatology Division, University of São Paulo, Sao Paulo, Brazil, ⁷Children's Institute, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
Background/Purpose: Subclinical cardiac involvement was previously described in juvenile idiopathic arthritis (JIA) patients, however there is no data regarding echocardiography and cardiac biomarkers evaluations in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].